CD155在结肠癌组织中的表达及其临床意义

Expression of CD155 in Colon Carcinoma and its Clinical Significance

目的探讨CD155(poliovirus receptor,PVR)在结肠癌组织中的表达及与其临床病理特征的关系。方法应用组织微阵列技术和免疫组化Envision二步法,检测72例结肠癌组织及72例结肠正常组织中CD155的表达情况。结果CD155在正常对照组无阳性表达,结肠癌组阳性表达率为41.18%,两组阳性表达率比较有显著性差异(P<0.005);不同分化程度、不同Dukes分期之间CD155的阳性表达率差异无显著性(P>0.995,P>0.750),CD155阳性表达强度与分化程度及Dukes分期无相关关系(P=0.665,P=0.768)。结论CD155在结肠癌发生的早期就已出现,并存在于结肠癌的整个发展进程,可以利用CD155与NK细胞激活性受体(CD226/CD96)的结合,进一步激活NK细胞对结肠癌的活化杀伤性作用,从而为结肠癌的免疫治疗提供新的思路。

Objective To explore the expression of CD155 in colon carcinoma and its clinical significance. Methods Tissue microarray（TMA） and immunohistochemistry（IHC） were used to investigate the expression of CD155 in 72 colon carcinoma and 72 normal colon tissues. Results Immunohistochemistric analysis revealed that the CD155 expression was negative in control group. The positive rate of CD155 expression was 41.18% in colon carcinoma. The expression of CD155 was significantly different between colon carcinoma and normal colon tissues （P 〈 0. 005 ）. The expression of CD155 had no significant differences in various tumor differentiation degrees and Dukes stages （P 〉 0. 995, P 〉 0. 750 ）. There were no correlations between CD155 expression intensity and tumor differentiation degrees as well as Dukes stages （ P = 0. 665, P = 0.768 ）. Conclusion The CD155 expression begins at an early stage in the tumorigenesis and continues to late stages. This provides a new immunotherapeutic method of colon cancer through binding CD155 with its corresponding lignnds - CD226/CD96 to enhance the NK-cell mediated antitumor function.